CLS updates the company brand and launches new website
Lund, Sweden – Clinical Laserthermia Systems AB (publ) (CLS) today announces that the company is launching a new website to further strengthen communication with the company's customers. The website is based on a new brand platform with clear messages about the benefits the company's products offer for effective and minimally invasive treatment with laser ablation, primarily for patients with tumor diseases.
"During this intensive commercial phase CLS is now entering, we are very pleased to launch a modern platform that takes our communication to the next level and creates clarity with our stakeholders around our focus areas: prostate cancer, neurosurgery and immune stimulation (imILT®)," says Lars-Erik Eriksson, Deputy CEO of CLS.
"Our new website has clear sections and information for different stakeholders. Initially this is mainly customers who want to read more about CLS TRANBERG® products and the therapeutic areas on which we are now focused. The webpage also shows how CLS's new technology can be integrated with existing hospital systems to achieve maximum treatment precision and effect. Later we aim to add more patient-oriented information to the website. Following requests, it is worth mentioning that we have also created a section that makes it possible to follow the overall development of our clinical programs," says Liselotte Nilsson, VP Marketing & Scientific Marketing, CLS.
The new website, designed for the European market, will be followed by versions specifically adapted for the US market and the rest of the world.
The information was submitted for publication on March 8, 2022 at 16:40 CET.
Contact Information:
Lars-Erik Eriksson, CFO and Deputy CEO, Clinical Laserthermia Systems AB (publ)
Phone: +46 – (0)702 – 90 33 00 E-mail: lars-erik.eriksson@clinicallaser.com
Liselotte Nilsson, VP Marketing & Scientific Marketing, Clinical Laserthermia Systems AB (publ)
Phone: +46 – (0)703 – 73 64 43, E-mail: lotta.nilsson@clinicallaser.se
About CLS and TRANBERG system
Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment with imILT®, the Company's interstitial laser thermotherapy for immunostimulant ablation with potential abscopal effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB, Tel: +46 8 528 00 399. E-mail: info@fnca.se.
For more information about CLS, please visit the Company's website: www.clinicallaser.se
Tags: